Latest News

Robert Hadden, MD  (Credit: LinkedIn)
Long-Term Safety and Low Relapse Rate Observed in Phase 3 ADVANCE-CIDP 3 Trial of Hyqvia

June 20th 2024

A phase 3 trial showed that over time, Hyqvia is a safe and well-tolerated maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.

Sarah Sheikh, MSc, BM, BCh, MRCP  (Credit: LinkedIn)
Soticlestat Shows Mixed Results in Phase 3 Studies of Dravet and Lennox-Gastaut Syndrome

June 20th 2024

New HEALEY-ALS Trial Results Show CNM-Au8’s Effect on Survival, Neurofilament Light
New HEALEY-ALS Trial Results Show CNM-Au8’s Effect on Survival, Neurofilament Light

June 19th 2024

Parkinson Therapy ND0612 Receives Complete Response Letter
Parkinson Therapy ND0612 Receives Complete Response Letter

June 19th 2024

Otsuka Halts Development of Alzheimer Disease Agitation Treatment AVP-786
Otsuka Halts Development of Alzheimer Disease Agitation Treatment AVP-786

June 19th 2024

Coverage of SLEEP 2024

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor of SLEEP 2024.

SLEEP 2024

Conference Coverage

View All
Treatment Decisions With Stable Multiple Sclerosis
Treatment Decisions With Stable Multiple Sclerosis

June 19th 2024

Switching From S1P-Modulating Therapies to Other DMTs
Switching From S1P-Modulating Therapies to Other DMTs

June 19th 2024

Eliciting Patient Voice to Help Optimize the Treatment and Management of Cataplexy: Anne Marie Morse, DO, FAASM
Eliciting Patient Voice to Help Optimize the Treatment and Management of Cataplexy: Anne Marie Morse, DO, FAASM

June 18th 2024

A Personalized Approach to Treating Gait Issues in Multiple Sclerosis: the Cionic Neural Sleeve
A Personalized Approach to Treating Gait Issues in Multiple Sclerosis: the Cionic Neural Sleeve

June 17th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.